European Neurology最新文献_第8页

Editorial. 社论

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-01-11 DOI: 10.1159/000528909

Julien Bogousslavsky

引用次数: 0

Radiological Disease Activity in Secondary Progressive Multiple Sclerosis. 继发性进行性多发性硬化的放射学疾病活动性。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 DOI: 10.1159/000527720

Daniela Noa Zohar, David Magalashvili, Sapir Dreyer-Alster, Chen Hoffmann, Gil Harari, Mark Dolev, Anat Achiron

{"title":"Radiological Disease Activity in Secondary Progressive Multiple Sclerosis.","authors":"Daniela Noa Zohar, David Magalashvili, Sapir Dreyer-Alster, Chen Hoffmann, Gil Harari, Mark Dolev, Anat Achiron","doi":"10.1159/000527720","DOIUrl":"https://doi.org/10.1159/000527720","url":null,"abstract":"Introduction: MRI activity is less frequent among secondary progressive multiple sclerosis (SPMS) patients. In the current study, we aimed to identify SPMS patients with higher radiological disease activity (RDA) and determine their clinical characteristics.Methods: We evaluated the occurrence of RDA in SPMS patients followed at the Sheba Multiple Sclerosis Center between January 1, 2015, and December 31, 2020. All patients underwent brain and spinal cord MRI examinations as a routine follow-up unrelated to clinical disease activity. Patients were subdivided into RDA and non-RDA MRI groups based on the presence of active gadolinium-enhancing T1 lesions and/or new/enlarging T2 lesions. Demographic variables and disease-related data were compared.Results: One hundred consecutive SPMS patients, 74 females, median age of 50 years, disease duration of 19.5 years, and neurological disability by the Expanded Disability Status Scale (EDSS) score of 6.0, were included in the study. The RDA group comprised 35 patients (35%), of them 65.7% (n = 23) exhibited only brain MRI activity, 22.8% (n = 8) only spinal cord MRI activity, and 11.4% (n = 4) had both. Patients in the RDA group were diagnosed at a younger mean (SD) age of 28.2 (8.9) versus 33.7 (10.1) years and were younger with a mean (SD) age of 47.8 (9.9) versus 53.4 (10.1) years, as compared with the non-RDA group. No significant differences were found in relation to disease duration, EDSS, exposure to immunomodulatory treatments, and duration of immunomodulatory treatments.Conclusions: RDA unrelated to clinical symptomatology was more frequent in a subgroup of young SPMS patients.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":"86 2","pages":"116-120"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9527509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Lasting COVID-Associated Brain Fog: A Follow-Up Study. 长期与新冠病毒相关的脑雾:一项后续研究。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 DOI: 10.1159/000529860

Ali A Asadi-Pooya, Mina Shahisavandi, Hamid Nemati, Afrooz Karimi, Anahita Jafari, Sara Nasiri, Seyyed Saeed Mohammadi, Meshkat Nemati, Zahra Rahimian, Hossein Bayat

{"title":"Long-Lasting COVID-Associated Brain Fog: A Follow-Up Study.","authors":"Ali A Asadi-Pooya, Mina Shahisavandi, Hamid Nemati, Afrooz Karimi, Anahita Jafari, Sara Nasiri, Seyyed Saeed Mohammadi, Meshkat Nemati, Zahra Rahimian, Hossein Bayat","doi":"10.1159/000529860","DOIUrl":"https://doi.org/10.1159/000529860","url":null,"abstract":"Introduction: We investigated the longevity of COVID-associated brain fog in patients who have survived the COVID-19.Methods: This was a follow-up study of 2,696 adult patients with COVID-19 from our previous study. We selected every other patient in our database. The follow-up data were collected during a phone call to the participants in January-February 2022 (11 months after the initial study): concentration difficulty and the patient's self-declared status in their ability to concentrate.Results: In total, 1,164 people were included; 35 people (3.0%) had concentration difficulty and 65 individuals (5.6%) had a worsened status in their ability to concentrate and think; 26 people (2.2%) responded yes to both questions and were considered as having long-lasting brain fog. People with long-lasting brain fog were more often admitted to ICUs during the initial hospitalization (23.1% vs. 9.3%; p = 0.032) compared with those without long-lasting brain fog.Conclusion: We may conclude that a minority of the hospitalized patients with COVID-19 may suffer from long-lasting post-COVID brain fog, at least for more than 1 year after their initial illness. Long-lasting post-COVID brain fog has a significant association with the severity of the initial illness.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":"86 3","pages":"166-170"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9788854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis. 干扰素Beta-1a与醋酸格拉默：一组多发性硬化症女性先天免疫的变化。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-07-20 DOI: 10.1159/000532022

Marek Peterka, Martin Valis, Ondrej Soucek, Jan Krejsek, Lukáš Sobisek, Ilona Sejkorova, Blanka Klimova, Pavel Stourac, Zbysek Pavelek, Michal Novotny

{"title":"Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.","authors":"Marek Peterka, Martin Valis, Ondrej Soucek, Jan Krejsek, Lukáš Sobisek, Ilona Sejkorova, Blanka Klimova, Pavel Stourac, Zbysek Pavelek, Michal Novotny","doi":"10.1159/000532022","DOIUrl":"10.1159/000532022","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations.Methods: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD).Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%.Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":" ","pages":"334-340"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10222155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Status Epilepticus by Different Pediatric Departments: Neurology, Intensive Care, and Emergency Medicine. 不同儿科对癫痫状态的管理：神经病学、重症监护和急诊医学。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-08-30 DOI: 10.1159/000533191

Özge Dedeoglu, Halise Akça, Serhat Emeksiz, Ayşe Kartal, Neşe Çıtak Kurt

{"title":"Management of Status Epilepticus by Different Pediatric Departments: Neurology, Intensive Care, and Emergency Medicine.","authors":"Özge Dedeoglu, Halise Akça, Serhat Emeksiz, Ayşe Kartal, Neşe Çıtak Kurt","doi":"10.1159/000533191","DOIUrl":"10.1159/000533191","url":null,"abstract":"Introduction: The aim of this study was to explore the differences in status epilepticus (SE) management among pediatric neurology, emergency medicine, and intensive care specialists in Turkey.Methods: A 22-item questionnaire regarding first-, second-, and third-line management strategies of SE including demographic characteristics and common etiologies according to the specialty of participants was mailed to 370 specialists working in Turkey.Results: A total of 334 participants (response rate 90%) comprising 136 pediatric neurologists, 102 pediatric emergency medicine specialists, and 96 pediatric intensive care specialists completed the survey. While intensive care specialists frequently managed SE due to metabolic and autoimmune reasons, the most common etiologies encountered by emergency medicine specialists were epilepsy and infections. More than half of the intensive care specialists (64.6%) reported using non-BZD antiseizure medications in the 5th minute of the seizure. Most of the neurologists (76.4%) preferred to administer intravenous (IV) levetiracetam infusion as a second-line agent. About half of intensive care specialists and neurologists tried immunomodulatory therapies in super-refractory SE. Intensive care and emergency medicine specialists were less likely to favor ketogenic diet and pyridoxine therapy for the treatment of super-refractory SE. The rate of requesting EEG monitoring to recognize nonconvulsive SE (NCSE) was found to be very low except for neurologists.Conclusion: There was no consensus among neurologists, intensive care specialists, and emergency medicine specialists in the management of SE in Turkey. Familiarity with particular antiseizure medications and the etiologies they manage seem to be the most important factors influencing the attitudes.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":" ","pages":"315-324"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10476400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

André-Thomas (1867-1963), Initiator of Neonatal Neurology. 安德雷·托马斯（1867-1963），新生儿神经病学的奠基人。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-09-01 DOI: 10.1159/000531863

Olivier Walusinski

引用次数: 0

Delirium and Dementia in the Elderly: Sometimes Associated or Always Together? 老年人谵妄和痴呆:有时相关还是总是相关?

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 DOI: 10.1159/000530226

Orso Bugiani

{"title":"Delirium and Dementia in the Elderly: Sometimes Associated or Always Together?","authors":"Orso Bugiani","doi":"10.1159/000530226","DOIUrl":"https://doi.org/10.1159/000530226","url":null,"abstract":"Background: In the elderly, the association of delirium and dementia can cause diagnostic problems because they share the same symptom of confusion. Delirium is often misdiagnosed as dementia and treated inappropriately, ignoring that it could be successfully addressed, which can lead to increased health risks up to death.Summary: Confusion indicates that functional reserve fails to compensate for the action of stressors. The decline in reserve is linked to aging-related changes in blood flow, mitochondria, cerebrospinal fluid, and immune function, as well as the appearance of structural precursors of disease. It is greater in dementia that adds a large burden of pathology, especially degenerative and vascular.Key messages: Based on their common background linking normal and pathological brain aging, it can be argued that delirium and dementia are always associated to some extent and can aggravate each other. The clinical approach to their association, which currently relies on the preliminary diagnosis of delirium according to ad hoc protocols, could be simplified by taking delirium for granted so that its causative stressors, usually the most common diseases of old age and/or drug abuse, could be addressed immediately. This approach would benefit all demented patients: not only those who are in such a serious condition that they need to be hospitalized due to the risk of death, but also those with clouded delirium.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":"86 3","pages":"161-165"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10147502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Patients with Encephalitis Lethargica Wake Up from Local Sleep? A Reply to Brigo et al. "You Are Older, although You Do Not Know That": Time, Consciousness, and Memory in "A Kind of Alaska" by Harold Pinter (1930-2008). 昏睡性脑炎患者能从局部睡眠中醒来吗?对Brigo等人的答复。“你变老了，尽管你不知道”:哈罗德·品特(1930-2008)《一种阿拉斯加》中的时间、意识和记忆。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 DOI: 10.1159/000527768

Angela Comanducci, Alessandro Viganò, Mario Meloni

引用次数: 1

The Diagnostic Performance of Laboratory Tests of Neurosyphilis: A Systematic Review and Network Meta-Analysis. 神经梅毒实验室检测的诊断性能：系统回顾与网络元分析

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-08-07 DOI: 10.1159/000531341

Duyu Ding, Junhua Gao, Wei Zhang, Dongmei Xu

{"title":"The Diagnostic Performance of Laboratory Tests of Neurosyphilis: A Systematic Review and Network Meta-Analysis.","authors":"Duyu Ding, Junhua Gao, Wei Zhang, Dongmei Xu","doi":"10.1159/000531341","DOIUrl":"10.1159/000531341","url":null,"abstract":"Introduction: The gold standard for diagnosing neurosyphilis (NS) is currently unavailable; various laboratory parameters in cerebrospinal fluid (CSF) and blood can assist in the diagnosis.Methods: PubMed, Embase, and the Cochrane Library were searched. Studies utilizing laboratory tests to assist in the diagnosis of NS were included. The pooled indicators for diagnostic performance and their respective 95% confidence intervals (CIs) were calculated. We used the superiority index to test the superiority of a diagnostic test.Results: Eleven citations were included in the study. Albumin quotient, CSF-TPHA, CSF-EIA, CSF-LDH, CSF-WBC, CSF-CXCL13, FTA-ABS, CSF-PCR, RPR, CSF-TPPA, TRUST, and CSF-venereal diseases research laboratory (VDRL) were assessed in the studies included. The pooled estimates of sensitivity, specificity, AUC of SROC and their respective 95% CIs for CSF-TPPA and CSF-VDRL were 0.97 (0.17, 1.00), 0.84 (0.62, 0.95), 0.93 (0.91, 0.95) and 0.74 (0.59, 0.85), 0.99 (0.93, 1.00), 0.94 (0.91, 0.96), respectively. CSF-TPHA demonstrated the highest relative sensitivity. CSF-VDRL manifested the highest specificity. CSF-TPHA, TRUST, CSF-VDRL, CSF-EIA, and RPR ranked in the top five laboratory tests with superiority index.Conclusion: CSF-TPHA, TRUST, CSF-VDRL, CSF-EIA, and RPR indicate acceptable performance in detecting NS compared to other modalities. Comprehensive diagnostic strategies still play a significant role in the diagnosis of NS.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":" ","pages":"418-429"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9944843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis. 低剂量利妥昔单抗治疗难治性重症肌无力的长期疗效和安全性。

IF 2.4 4区医学

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-09-30 DOI: 10.1159/000534336

Jingru Ren, Jianchun Wang, Ran Liu, Yunyi Jin, Jing Guo, Yan Yao, Jingjing Luo, Hongjun Hao, Feng Gao

{"title":"Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.","authors":"Jingru Ren, Jianchun Wang, Ran Liu, Yunyi Jin, Jing Guo, Yan Yao, Jingjing Luo, Hongjun Hao, Feng Gao","doi":"10.1159/000534336","DOIUrl":"10.1159/000534336","url":null,"abstract":"Introduction: Rituximab is a monoclonal chimeric antibody against CD20+ B cells. We aimed to assess the long-term efficacy and safety of CD20+ B cell-guided treatment with low-dose rituximab in refractory myasthenia gravis patients.Methods: Patients with refractory myasthenia gravis treated with rituximab for more than 2 years were included. Rituximab was administered when CD20+ B cells were greater than 1%. We analysed the efficacy of rituximab, treatment interval, side effects, prognosis, and treatment course.Results: A total of 22 patients were included. All patients received 2-12 doses of rituximab, and the median follow-up time was 48.5 months. The scores of the Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Composite were significantly lower than those at baseline (p < 0.05). MGFA-PIS was significantly improved in 21 (95.45%) patients and 14 (63.64%) patients have reached MGFA-PIS minimal manifestations. The average daily dose of prednisone and pyridostigmine bromide and the proportion of immunosuppressants were significantly lower (p < 0.05). Seven patients suffered from 14 worsenings. Eight patients terminated rituximab due to good efficacy. Most patients tolerated rituximab well, although 1 patient had opportunistic infection and hypogammaglobulinemia, 1 patient had an intracranial mass.Conclusion: Long-term CD20+ B-cell-guided low-dose rituximab showed good efficacy and tolerance in patients with refractory myasthenia gravis.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":" ","pages":"387-394"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0